ABG
INFI

Ally Bridge Group’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Ally Bridge Group’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-86,242
Closed -$103K – 42
2022
Q3 		$103K Buy
+86,242
New +$93K 0.07% 39

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GC
Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Ally Bridge Group's INFI Position: Q4 2022 in Review

Ally Bridge Group sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q4 2022, closing a stake of 86,242 shares — an estimated $103K sold.

Ally Bridge Group first reported a position in INFI in Q3 2022 and held it in 1 quarter. The position peaked at $103K in Q3 2022. 68 funds tracked by Wall St. Rank hold INFI as of Q4 2022.

  • Ally Bridge Group reported no remaining Infinity Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Ally Bridge Group sold 86,242 Infinity Pharmaceuticals, Inc. shares in Q4 2022, an estimated $103K.
  • Ally Bridge Group first reported a position in Infinity Pharmaceuticals, Inc. in Q3 2022 and held it in 1 quarter.
  • Ally Bridge Group's Infinity Pharmaceuticals, Inc. position peaked at $103K in Q3 2022.
  • 68 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q4 2022.

Based on Ally Bridge Group's 13F filing for Q4 2022, filed 14 Feb 2023.